Germany Drug Patents

« Back to Dashboard

Drug Patents in Germany and US Equivalents

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

Patent Number	Estimated Expiration	Equivalent US Patent	US Expiry Date	Generic Name	US Applicant	US Tradename
19975058		5034394	2012-06-18	abacavir sulfate	Viiv Hlthcare	ZIAGEN
68921798		5034394	2012-06-18	abacavir sulfate	Viiv Hlthcare	ZIAGEN
69033197		5034394	2012-06-18	abacavir sulfate	Viiv Hlthcare	ZIAGEN
69033252		5034394	2012-06-18	abacavir sulfate	Viiv Hlthcare	ZIAGEN
19975058		5089500	2009-12-26	abacavir sulfate	Viiv Hlthcare	ZIAGEN
68921798		5089500	2009-12-26	abacavir sulfate	Viiv Hlthcare	ZIAGEN
69033197		5089500	2009-12-26	abacavir sulfate	Viiv Hlthcare	ZIAGEN

Key Insights for Patentability, Enforceability, and Scope of Claims for Biopharmaceutical Patents in the Germany Patent Office

Last updated: February 20, 2026

What are the criteria for patentability of biopharmaceutical inventions in Germany?

The European Patent Convention (EPC), which Germany adheres to, sets the foundational standards for patentability. These include novelty, inventive step, and industrial applicability. Specific considerations for biopharmaceuticals are governed by German patent law and the European Patent Office (EPO) guidelines.

Patentability Requirements

• Novelty: The invention must be new. Prior disclosures in scientific literature, patents, or public use can invalidate claims.
• Inventive Step: The invention must not be obvious to a person skilled in the field. Any prior art references that render the invention obvious will nullify patentability.
• Industrial Applicability: The invention must have a specific, substantial, and credible utility.

Exclusions and Limitations

• Naturally Occurring Substances: Product claims related to naturally occurring substances are often rejected unless the invention involves a significant modification or specific method of production.
• Methods of Treatment: surgical or therapeutic methods are generally not patentable under German and EPC law.
• Biological Material: Patentability depends on whether the biological material is isolated and characterized sufficiently to distinguish it from its natural state. The isolation must involve an inventive step.

How does Germany assess the novelty and inventive step of biopharmaceutical patents?

Novelty

• Considers all prior disclosures, including scientific articles, presentations, or prior patents. Public use or offer for sale within 10 years prior to filing can jeopardize novelty.
• The scope extends to biological sequences, chemical entities, and methods if adequately disclosed.

Inventive Step

• Must demonstrate a non-obvious technical effect beyond prior art.
• Often challenged based on known biological pathways, existing compounds, or standard techniques.

Example: Patent examiners may reject a claim on a new antibody if a similar antibody targeting the same antigen was previously disclosed, unless the claimed antibody has a novel binding site or improved efficacy.

What are enforceability considerations for biopharmaceutical patents in Germany?

Patent Life and Maintenance

• Ten-year patent term, with possible extensions for certain biologics under supplementary protection certificates (SPCs).
• Annual maintenance fees start at around €470 in the third year and increase over time; non-payment causes patent lapse.

Challenges to Enforceability

• Oppositions and Nullity Actions: Filed within nine months of grant, often based on lack of novelty or inventive step.
• Patent Infringement: Enforced through civil courts; defenses may include prior use, experimental use, or patent invalidity.
• Subject Matter Challenges: Due to the EPC rules, claims involving biological material can be challenged on sufficiency of disclosure or added matter.

Special Considerations for Biopharmaceuticals

• Patent validity can be compromised by subsequent discoveries revealing that the claimed invention is not as broad as initially claimed.
• Biological complexity and method claims can provide narrow enforcement scope, demanding precise claim language.

How broad can the scope of claims be for biopharmaceutical patents in Germany?

Claim Types and Strategies

• Product Claims: Cover specific molecules such as active compounds, antibodies, or genetic sequences.
• Use Claims: Focus on therapeutic applications or methods of treatment.
• Process Claims: Cover methods of manufacturing biologics.

Scope and Limitations

• Product claims are often limited to the exact biological entity unless the claims are "Swiss-type" or "second medical use" claims.
• Use claims are constrained by the requirement of "credible utility" and novelty.
• Broad claims require a thorough description that supports such scope, including sufficient biological data to demonstrate utility and inventive aspects.

Patent Specifications

• Must enable the skilled person to reproduce the invention.
• Biological material claims, such as cell lines or genetic sequences, require deposits or detailed descriptions.
• Claim drafting often aims for a broad composition of matter with narrower dependent claims to withstand attack.

Summary table of key points

Aspect	Details
Patentability	Novelty, inventive step, industrial applicability
Non-patentable subject matter	Naturally occurring substances, methods of treatment
Biological material claims	Require inventive modification, deposit or detailed description
Enforceability	Validity challenges, maintenance fees, scope limitations
Claim scope	Product, use, and process claims; broad claims require detailed support

Key Takeaways

• Germany applies EPC standards for biopharmaceutical patenting, with strict novelty and inventive step assessments.
• Biological inventions must involve significant modification or inventive steps for patentability.
• Claims should be crafted carefully to balance broad coverage with permissible scope under legal standards.
• Validation and enforcement depend on meticulous documentation and proactive patent management.
• Biological material claims require concrete descriptions or deposits; broad claims face heightened scrutiny.

Frequently Asked Questions

1. Can naturally occurring genes be patented in Germany?
   Only if isolated, characterized, and significantly modified from their natural state, demonstrating an inventive step.

2. Are method of treatment claims patentable in Germany?
   No, surgical and therapeutic methods are excluded from patentability under EPC and German law.

3. What strategies improve claim scope for biopharmaceutical inventions?
   Use combinations of product, use, and process claims with detailed descriptions to broaden protection while remaining compliant.

4. How long is the patent protection for biopharmaceuticals in Germany?
   20 years from the filing date, with possible extensions via SPCs for certain biologics.

5. What are common grounds for patent opposition in Germany?
   Lack of novelty, obviousness, insufficient disclosure, or added matter are primary grounds [1].

---

References

[1] European Patent Office. (2022). Guidelines for Examination in the EPO. https://www.epo.org/law-practice/legal-texts/guidelines.html